MedPage Today

Here's the Data Supporting Pegcetacoplan's Approval in Two Rare Kidney Diseases

Affecting roughly 5,000 people in the U.S., C3 glomerulopathy and immune-complex MPGN are two rare glomerulopathies ...

Janux Therapeutics: Downgrading To 'Hold' Rating After Latest Updated Phase 1 JANX007 mCRPC Data

Janux Therapeutics' cash runway is about 12 months; dilution is likely, and upcoming data from both JANX007 and JANX008 are ...

Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today issued a comprehensive update on its therapeutic pipeline. The Company detailed meaningful ...
The Manila Times

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no ...
Science Daily

A common constipation drug shows a surprising ability to protect kidneys

A surprising link between constipation and kidney decline led researchers to test lubiprostone, revealing that it can protect ...

Vera Therapeutics, Inc. (VERA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Citi Annual Global Healthcare Conference 2025 December 3, 2025 4:00 PM ESTCompany ParticipantsMarshall Fordyce - ...